Research programme: biodefence therapeutics - Evolva/Summit

Drug Profile

Research programme: biodefence therapeutics - Evolva/Summit

Alternative Names: Biodefense therapeutics - Evolva/Summit; EV 009; EV-009-4400; SMT-15000

Latest Information Update: 20 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Summit plc
  • Developer Evolva Holding SA; Summit plc
  • Class Imino sugars; Small molecules
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Viral infections

Most Recent Events

  • 07 Sep 2010 Preclinical development in Viral infections and Bacterial infections due to biowarfare is continuing in the UK (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top